In 2019 @MedDiscCat joined forces with @CFTrust and more recently @Lifearc1 to form the Cystic Fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR).
🌕 Congratulations to King's College London and the UK Health Security Agency, who have recently joined our CDP portfolio.
More on this story here https://t.co/0VWPY7zC95
#CysticFibrosis#AMR
Thats a wrap! 🎬
A great few days at the #AMRConference2025, filled with insightful talks and valuable discussions with innovators and members of the #AMR community on tackling current challenges and driving change.
Connect with us through our website: https://t.co/eTz9GBGmYd
Missed us at #BioInfect? The CF AMR team will be at the 9th #AMRConference in Basel next week, with a poster on the Collaborative Discovery Programme.
Take advantage of the conference’s 1-1 partnering platform, or stop by and say hello!
🔗https://t.co/s2rhcy9Jr2
Today, we are at #BioInfect2025, listening to great talks from innovators and funders. If you're here, stop by the posters and learn about the work we are doing to help drive drug and diagnostic development.
#CysticFibrosis#AMR@Bionow
Today, we are at #BioInfect2025, listening to great talks from innovators and funders. If you're here, stop by the posters and learn about the work we are doing to help drive drug and diagnostic development.
#CysticFibrosis#AMR@Bionow
Congratulations to @GloxThera! Glox Therapeutics are looking to progress their novel programme aimed at targeting P.aeruginosa infections in Cystic Fibrosis. We’re excited to have them onboard the CDP funding call.
https://t.co/cQ8l8Jn4vN
@cftrust | @MedDiscCat | @lifearc1
🌕 Watch the House of Lords Science & Technology Committee's session on #phages! Exploring how phages could be used as an alternative to traditional #antibiotics & the challenges that need to be overcome to make this treatment more widely available.
https://t.co/pCVPXsw8nF
🌕 Fantastic day @FacultyPharmMed's annual symposium. Great to have been part of the discussion on integrating lived experience early in product development and the impact of this approach on R&D efforts.
🏆 We’re honoured to receive the Most Impactful Collaboration Award at the @OBN_UK ceremony last night. A heartfelt thank you to everyone who's been part of this incredible journey including our partners and the wider CF community.
Read more: https://t.co/a6XGnLdNQo
A key call to action in this year’s #WAAW campaign is around taking concrete actions in response to the threat of AMR. We’ve announced 4 of 6 awardees to receive funding from our collaborative discovery programme.
https://t.co/KkK0oRHjuD
🌕 In the lead-up to #WAAW next week, Aaron reminds us of the reality faced by some people living with #CysticFibrosis, highlighting why new treatments are still needed. Join us next week as we get behind this important campaign.
https://t.co/1yWe95Nvb5
@WHO#WAAW24#AMR
We’re delighted to announce another successful awardee from our CDP funding call. Rostra Therapeutics are looking to progress its novel programme aimed at targeting fungal infections in #CysticFibrosis.
More here https://t.co/gxIRUc1RX8
@lifearc1 | @cftrust | @MedDiscCat
📢 Next month, we’re speaking at the @FacultyPharmMed Annual Symposium! We’ll share insights on our TPP development, collaborating with those with lived experience, and the impact on R&D.
🔗: https://t.co/iQH4LI9pqK
@lifearc1@MedDiscCat@cftrust
Our quarterly newsletter will be going out soon-are you signed up to receive it? 🗞️
Don't miss out, keep up to date with all our news and events, sign up here: https://t.co/QK6iTAO7Cj
#Newsletter#CFAMR
We are at the iCare course this week. Fantastic coming together with experts in the #AMR field learning about some of the state-of-the-art approaches to antimicrobial #DrugDiscovery.
We’re excited to announce @Bicycle_tx as part of the first cohort in our Collaborative Discovery Programme. They’re developing a new class of antibiotics targeting P. aeruginosa infections for CF-related lung issues.
More details here: https://t.co/xfbE7aFglr